Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phytonadione
Drug ID BADD_D01770
Description Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin.[L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X.[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity of vitamin K.[L33319] Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the FDA prior to 1955.[L33389]
Indications and Usage For the treatment of haemorrhagic conditions in infants, antidote for coumarin anticoagulants in hypoprothrombinaemia.
Marketing Status Prescription; Discontinued
ATC Code B02BA01
DrugBank ID DB01022
KEGG ID D00148
MeSH ID D010837
PubChem ID 5284607
TTD Drug ID D00FSV
NDC Product Code 50090-4523; 52584-405; 68682-170; 0409-9158; 50268-661; 49812-0232; 76055-0006; 0187-1704; 69238-1051; 60687-381; 70710-1014; 0409-9157; 63238-4300; 52584-046; 14501-0027; 0404-9969; 50090-4521; 50090-1753; 16714-973; 43598-405; 33656-0010; 0404-9935; 42413-0192; 65571-0028; 76339-107; 76329-1240; 70771-1318; 0904-6882; 52221-124
Synonyms Vitamin K 1 | Phytonadione | Vitamin K1 | Phytomenadione | Phylloquinone | Phyllohydroquinone | Aquamephyton | Konakion
Chemical Information
Molecular Formula C31H46O2
CAS Registry Number 79083-00-4
SMILES CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Atrophy08.03.04.001--Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.002--
Death08.04.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspnoea22.02.01.004; 02.01.03.002--
Erythema23.03.06.001--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Heart rate increased13.14.04.002--Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.003--Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction08.02.03.014; 12.07.03.015--
Necrosis24.04.02.006; 08.03.03.001--Not Available
Pain08.01.08.004--
Phlebitis24.05.03.001; 12.02.01.002--
Pruritus23.03.12.001--
Pulse abnormal13.14.04.004--Not Available
Pulse pressure decreased13.14.04.008--Not Available
Rash erythematous23.03.06.003--Not Available
Scleroderma23.03.02.005; 15.06.01.002; 10.04.07.001--Not Available
Swelling08.01.03.015--Not Available
Induration08.01.03.020--Not Available
Inflammation08.01.05.007--Not Available
The 1th Page    1    Total 1 Pages